Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to...
-
Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics
Unconditional payment of $3.5 million Contingent payment of up to additional $17 million plus royaltiesSeelos to receive rights also to the Trehalose for Sanfilippo Syndrome Program Tel Aviv,...
-
Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a...
-
Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced...
-
Enlivex Therapeutics is a private, venture-funded clinical stage immunotherapy company developing an allogeneic drug pipeline for immune system rebalancing, which is critical for the treatment of...
-
TEL AVIV, Israel and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an organization...
-
TEL AVIV, Israel, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
-
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on September 25, 2017 TEL AVIV, Israel, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a clinical-stage,...
-
TEL AVIV, Israel, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
-
JSB-Partners Engaged to Lead the Effort Company Receives Regulatory Clearance to Initiate a Phase 2b trial of Trehalose in OPMD patients TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) --...